Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine

References

• Alper, K. R. 2001. Ibogaine: A review. The Alkaloids: Chemistry and Biology 56:1–38.
   PubMedGoogle Scholar
• Alper, K. R., H. S. Lotsof, G. M. Frenken, D. J. Luciano, and J. Bastiaans. 1999. Treatment of acute opioid withdrawal with ibogaine. The American Journal on Addictions/American Academy of Psychiatrists in Alcoholism and Addictions 8 (3):234–42. doi:10.1080/105504999305848.
   PubMed Web of Science ®Google Scholar
• Alper, K. R., H. S. Lotsof, G. M. Frenken, D. J. Luciano, and J. Bastiaans. 2000. Ibogaine in acute opioid withdrawal: An open label case series. Annals of the New York Academy of Sciences 909:257–59. doi:10.1111/j.1749-6632.2000.tb06687.x.
   PubMed Web of Science ®Google Scholar
• Andrew, T. D., G. E. Bigelow, J. A. Harrison, R. E. Johnson, P. J. Fudala, and E. C. Strain. 2009. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug and Alcohol Dependence 105 (1–2):154–59. doi:10.1016/j.drugalcdep.2009.07.001.
   PubMed Web of Science ®Google Scholar
• Antonio, T., S. R. Childers, R. B. Rothman, C. M. Dersch, C. King, M. Kuehne, W. G. Bornmann, A. J. Eshleman, A. Janowsky, E. R. Simon, M. E. Reith, and K. Alper. 2013. Effect of iboga alkaloids on micro-opioid receptor-coupled G protein activation. PLoS One 8 (10):e77262. doi:10.1371/journal.pone.0077262.
   PubMed Web of Science ®Google Scholar
• APA. 2013. Diagnostic and statistical manual of mental disorders: DSM-5. Arlington, VA: American Psychiatric Publishing.
   Google Scholar
• Asua, I. 2013. Growing menace of ibogaine toxicity. British Journal of Anaesthesia 111 (6):1029–30. doi:10.1093/bja/aet396.
   PubMed Web of Science ®Google Scholar
• Bogenschutz, M. P., A. A. Forcehimes, J. A. Pommy, C. E. Wilcox, P. C. Barbosa, and R. J. Strassman. 2015. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology 29 (3):289–99. doi:10.1177/0269881114565144.
   PubMed Web of Science ®Google Scholar
• Brown, T. K. 2013. Ibogaine in the treatment of substance dependence. Current Drug Abuse Reviews 6 (1):3–16. doi:10.2174/15672050113109990001.
   PubMedGoogle Scholar
• Brown, T. K., and K. Alper. 2017. Treatment of opioid use disorder with ibogaine: Detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse 1–13. doi:10.1080/00952990.2017.1320802.
   Web of Science ®Google Scholar
• CDC. 2016. Wide-ranging online data for epidemiologic research (WONDER., Atlanta, GA: National Center for Health Statistics. http://wonder.cdc.gov.
   Google Scholar
• Davis, A. K., J. P. Barsuglia, A.-M. Windham-Herman, M. Lynch, and M. Polanco. 2017. Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning. Journal of Psychedelic Studies 1 (2):1–9. doi:10.1556/2054.01.2017.009.
   Google Scholar
• Dickinson, M. J., C. Wilkins, C. Fitzsimmons, P. Guion, T. Paterson, D. Greene, and B. R. Chaves. 2015. Clinical guidelines for ibogaine-assisted detoxification. Global Ibogaine Therapy Alliance. https://www.ibogainealliance.org/guidelines/ (accessed June 27, 2017).
   Google Scholar
• Dunlap, B., and A. S. Cifu. 2016. Clinical management of opioid use disorder. JAMA 316 (3):338–39. doi:10.1001/jama.2016.9795.
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu, A., R. R. Griffiths, and M. W. Johnson. 2014. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews 7 (3):157–64. doi:10.2174/1874473708666150107121331.
   PubMedGoogle Scholar
• Glue, P., M. Lockhart, F. Lam, N. Hung, C. T. Hung, and L. Friedhoff. 2015a. Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of Clinical Pharmacology 55 (2):189–94. doi:10.1002/jcph.404.
   PubMed Web of Science ®Google Scholar
• Glue, P., H. Winter, K. Garbe, H. Jakobi, A. Lyudin, Z. Lenagh-Glue, and C. T. Hung. 2015b. Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. Journal of Clinical Pharmacology 55 (6):680–87. doi:10.1002/jcph.471.
   PubMed Web of Science ®Google Scholar
• Han, B., W. M. Compton, C. M. Jones, and R. Cai. 2015. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003–2013. JAMA 314 (14):1468–78. doi:10.1001/jama.2015.11859.
   PubMed Web of Science ®Google Scholar
• Handelsman, L., K. J. Cochrane, M. J. Aronson, R. Ness, K. J. Rubinstein, and P. D. Kanof. 1987. Two new rating scales for opiate withdrawal. The American Journal of Drug and Alcohol Abuse 13 (3):293–308. doi:10.3109/00952998709001515.
   PubMed Web of Science ®Google Scholar
• Hildyard, C., P. Macklin, B. Prendergast, and Y. Bashir. 2016. A case of QT prolongation and torsades de pointes caused by ibogaine toxicity. The Journal of Emergency Medicine 50 (2):e83–7. doi:10.1016/j.jemermed.2015.06.051.
   PubMed Web of Science ®Google Scholar
• Jenks, C. W. 2002. Extraction studies of Tabernanthe iboga and Voacanga africana. Natural Product Letters 16 (1):71–76. doi:10.1080/1057563029001/4881.
   PubMed Web of Science ®Google Scholar
• Jones, J. D., M. A. Sullivan, S. K. Vosburg, J. M. Manubay, S. Mogali, V. Metz, and S. D. Comer. 2015. Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users. Addiction Biology 20 (4):784–98. doi:10.1111/adb.12163.
   PubMed Web of Science ®Google Scholar
• Krebs, T. S., and P. O. Johansen. 2012. Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. Journal of Psychopharmacology 26 (7):994–1002. doi:10.1177/0269881112439253.
   PubMed Web of Science ®Google Scholar
• Litjens, R. P., and T. M. Brunt. 2016. How toxic is ibogaine? Clinical Toxicology 54 (4):297–302. doi:10.3109/15563650.2016.1138226.
   PubMed Web of Science ®Google Scholar
• Luciano, D. 1998. Observations on treatment with ibogaine. The American Journal on Addictions/American Academy of Psychiatrists in Alcoholism and Addictions 7 (1):89–90. doi:10.1111/j.1521-0391.1998.tb00472.x.
   PubMed Web of Science ®Google Scholar
• Marta, C. J., W. C. Ryan, A. Kopelowicz, and R. J. Koek. 2015. Mania following use of ibogaine: A case series. The American Journal on Addictions/American Academy of Psychiatrists in Alcoholism and Addictions 24 (3):203–05. doi:10.1111/ajad.12209.
   PubMed Web of Science ®Google Scholar
• Mash, D. C., C. A. Kovera, J. Pablo, R. Tyndale, F. R. Ervin, J. D. Kamlet, and W. L. Hearn. 2001. Ibogaine in the treatment of heroin withdrawal. The Alkaloids: Chemistry and Biology 56:155–71.
   PubMedGoogle Scholar
• Mattick, R. P., C. Breen, J. Kimber, and M. Davoli. 2014. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2:Cd002207. doi:10.1002/14651858.CD002207.pub4.
   PubMed Web of Science ®Google Scholar
• McLellan, A. T., H. Kushner, D. Metzger, R. Peters, I. Smith, G. Grissom, H. Pettinati, and M. Argeriou. 1992. The fifth edition of the addiction severity index. Journal of Substance Abuse Treatment 9 (3):199–213. doi:10.1016/0740-5472(92)90062-S.
   PubMed Web of Science ®Google Scholar
• Muhuri, P. K., J. C. Gfroerer, and C. Davies. 2013. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality.
   Google Scholar
• Noller, G. E., C. M. Frampton, and B. Yazar-Klosinski. 2017. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse 44 (1):1–10. doi:10.1080/00952990.2017.1310218.
   Web of Science ®Google Scholar
• O’Connell, C. W., R. R. Gerona, M. W. Friesen, and B. T. Ly. 2015. Internet-purchased ibogaine toxicity confirmed with serum, urine, and product content levels. The American Journal of Emergency Medicine 33 (7):985.e5–6. doi:10.1016/j.ajem.2014.12.023.
   Web of Science ®Google Scholar
• Pablo, J. P., and D. C. Mash. 1998. Noribogaine stimulates naloxone-sensitive [35S]GTPgammaS binding. Neuroreport 9 (1):109–14. doi:10.1097/00001756-199801050-00022.
   PubMed Web of Science ®Google Scholar
• Popik, P., R. T. Layer, and P. Skolnick. 1995. 100 years of ibogaine: Neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacological Reviews 47 (2):235–53.
   PubMed Web of Science ®Google Scholar
• Quality, Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and. 2015. Behavioral health trends in the United States: Results fromthe 2014 national survey on drug use and health. Washington, DC: Dept of Health and Human Services.
   Google Scholar
• Schenberg, E. E., M. A. De Castro Comis, J. F. Morel Alexandre, L. F. Tófoli, B. D. Rasmussen Chaves, and D. X. Da Silveira. 2017. A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment. Journal of Psychedelic Studies 1 (2):1–10. doi:10.1556/2054.01.2017.007.
   Google Scholar
• Sheppard, S. G. 1994. A preliminary investigation of ibogaine: Case reports and recommendations for further study. Journal of Substance Abuse Treatment 11 (4):379–85. doi:10.1016/0740-5472(94)90049-3.
   PubMed Web of Science ®Google Scholar
• Smyth, B. P., J. Barry, E. Keenan, and K. Ducray. 2010. Lapse and relapse following inpatient treatment of opiate dependence. Irish Medical Journal 103 (6):176–79.
   PubMedGoogle Scholar
• Somoza, E., S. Dyrenforth, J. Goldsmith, J. Mezinskis, and M. Cohen 1995. In search of a universal drug craving scale. Paper presented at the Annual Meeting of the American Psychiatric Association, Miami, Florida, May 20–25.
   Google Scholar
• Thomas, G., P. Lucas, N. R. Capler, K. W. Tupper, and G. Martin. 2013. Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada. Current Drug Abuse Reviews 6 (1):30–42. doi:10.2174/15733998113099990003.
   PubMedGoogle Scholar
• Thomas, K., B. Malcolm, and D. Lastra. 2017. Psilocybin-assisted therapy: A review of a novel treatment for psychiatric disorders. Journal of Psychoactive Drugs 1–10. doi:10.1080/02791072.2017.1320734.
   PubMed Web of Science ®Google Scholar
• Wesson, D. R., and W. Ling. 2003. The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs 35 (2):253–59. doi:10.1080/02791072.2003.10400007.
   PubMed Web of Science ®Google Scholar
• Winkelman, M. 2014. Psychedelics as medicines for substance abuse rehabilitation: Evaluating treatments with LSD, peyote, ibogaine and ayahuasca. Current Drug Abuse Reviews 7 (2):101–16. doi:10.2174/1874473708666150107120011.
   PubMedGoogle Scholar